Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis.

@article{Behm2007EfficacyOI,
  title={Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis.},
  author={Brian W. Behm and Stephen J. Bickston},
  journal={Current treatment options in gastroenterology},
  year={2007},
  volume={10 3},
  pages={171-7}
}
Infliximab is arguably the first major advance in therapy for inflammatory bowel disease in more than a quarter of a century. Although it is important to distinguish efficacy from effectiveness, the data from clinical practice mirror those from randomized controlled trials. Infliximab has proven efficacious for luminal manifestations of Crohn's disease (CD) regardless of location. It also has proven efficacy in the subset of penetrating disease to the skin and perianal area, and it increases… CONTINUE READING